Indivior Submits New Drug Application to U.S. FDA for RBP-7000 Risperidone Monthly Depot for Treatment of Schizophrenia10.02.2017 | PDF Version
Enters Into Agreement with DURECT to Expand Patent Estate for RBP-7000
Slough, UK, 2 October 2017 – Indivior PLC (LON: INDV) today announced that its U.S. subsidiary, Indivior Inc. successfully submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) on September 28, 2017 to seek marketing approval for RBP-7000, Indivior’s investigational, once-monthly injectable risperidone in the ATRIGEL® delivery system for the treatment of schizophrenia. This NDA submission includes the results from the pivotal Phase 3 study assessing the efficacy and safety of RBP-7000 and an open-label, long-term safety study. In the pivotal randomized, double-blind, placebo-controlled study (RB-US-09-0010), RBP-7000 demonstrated statistically clinical improvement compared to placebo based on changes in mean Positive and Negative Syndrome Scale (PANSS) total and Clinical Global Impression-Severity of Illness (CGI-S) scores at 8 weeks.
“Schizophrenia is a devastating, chronic, and relapsing illness, and one of the most difficult aspects of treating patients successfully is nonadherence to prescribed treatments,” stated Christian Heidbreder, Ph.D., Chief Scientific Officer of Indivior. “The U.S. filing of RBP-7000 represents a significant milestone for Indivior in addressing unmet patient needs in schizophrenia and is a demonstration of our ongoing commitment to developing innovative treatment options and in helping to battle the challenges associated with this serious disease.”
Indivior also announced that it has entered into a definitive agreement with DURECT Corporation to purchase certain patent rights that further enhance RBP-7000’s intellectual property position. The purchase includes U.S. Patent No. 9,597,402 and pending applications in the same family. Consideration includes an upfront payment of $12.5 million, a payment of $5 million upon NDA approval of RBP-7000 and earn-out payments that are based on a low single digit percentage of U.S. net sales of certain products covered by the patent rights.
RBP-7000 IS AN INVESTIGATIONAL PRODUCT WHOSE SAFETY AND EFFICACY IS CURRENTLY UNDER REVIEW BY THE U.S. FOOD AND DRUG ADMINISTRATION.
RBP-7000 is a novel extended-release product using the ATRIGEL® delivery system for the subcutaneous (SC) administration of risperidone once every month for the treatment of schizophrenia.
The results of the pivotal Phase 3 study to assess the efficacy, safety and tolerability of RBP-7000 in subjects with acute schizophrenia were recently published.1,2
The most common adverse reactions in the clinical trials (reported in ≥ 5% and greater than placebo group) were weight increase, constipation, sedation/somnolence, pain in extremity, back pain, akathisia, anxiety and musculoskeletal pain. The most common injection site reactions (≥ 5%) were injection site pain, erythema and induration/nodule.
About Schizophrenia and Long-Acting Medicines
Schizophrenia is a chronic disorder characterized by a life-long pattern of acute psychotic episodes superimposed upon chronically poor psychosocial adjustment. The symptoms can be grouped into four domains: positive (for example, delusions, hallucinations, disorganized speech and behavior); negative (for example, social withdrawal, avolition, blunted effect); cognitive (for example, impaired sustained attention, executive function and working memory) and affective (for example, anxiety and depression, hostility and aggression, increased risk of suicide) symptoms. These occur in different combinations and to a different degree in each patient. Given the extensive heterogeneity of symptoms among individual patients, schizophrenia can be considered a clinical syndrome rather than a single disease entity. An estimated 23 million people worldwide are affected with schizophrenia.3 The median lifetime prevalence of schizophrenia has been reported to be 4/1,000 people4 whereas the median incidence of schizophrenia reported was 15.2 per 100,000 persons.5 Schizophrenia leads to high direct and indirect costs and accounts for 1.5–3 % of national healthcare expenditures across countries.6
Long-acting injectable antipsychotics provide patients with steady-state plasma concentrations of active drug that remain within a therapeutic range for an extended period of time and allow healthcare providers to track patient adherence. Although results cannot be easily generalized, there is common agreement to conclude that long-acting antipsychotics contribute to reduce relapses and hospitalizations, improve compliance, and are cost effective.6
Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy and health policy while providing education on evidence-based treatment models that have revolutionized modern addiction treatment. The name is the fusion of the words individual and endeavour, and the tagline “Focus on you” makes the Company’s commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder and schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 1000 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more.
This announcement contains certain statements that are forward-looking and which should be considered, amongst other statutory provisions, in light of the safe harbour provisions of the United States Private Securities Litigation Reform Act of 1995. By their nature, forward-looking statements involve risk and uncertainty as they relate to events or circumstances that may or may not occur in the future. Actual results may differ materially from those expressed or implied in such statements because they relate to future events. Forward-looking statements include, among other things, statements regarding the Indivior Group’s financial guidance for 2017 and its medium- and long-term growth outlook, its operational goals, its product development pipeline and statements regarding ongoing litigation.
Various factors may cause differences between Indivior’s expectations and actual results, including: factors affecting sales of Indivior Group’s products; the outcome of research and development activities; decisions by regulatory authorities regarding the Indivior Group’s drug applications; the speed with which regulatory authorizations, pricing approvals and product launches may be achieved; the outcome of post-approval clinical trials; competitive developments; difficulties or delays in manufacturing; the impact of existing and future legislation and regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment; legislation or regulatory action affecting pharmaceutical product pricing, reimbursement or access; claims and concerns that may arise regarding the safety or efficacy of the Indivior Group’s products and product candidates; risks related to legal proceedings; the Indivior Group’s ability to protect its patents and other intellectual property; the outcome of patent infringement litigation relating to Indivior Group’s products, including the ongoing ANDA lawsuits; changes in governmental laws and regulations; issues related to the outsourcing of certain operational and staff functions to third parties; uncertainties related to general economic, political, business, industry, regulatory and market conditions; and the impact of acquisitions, divestitures, restructurings, internal reorganizations, product recalls and withdrawals and other unusual items.
+44 207 353 4200
Jason Thompson, Indivior
Vice President, Investor Relations